Introduction
A variety of chromosomal aberrations in hematological malignancies have been identified and characterized.
Recent studies have demonstrated that several chromosomal rearrangements and molecular abnormalities are strongly associated with distinct clinical subgroups, and are predictive of clinical features and therapeutic responses (Look, 1997; Rowley, 1998) . The 11q23 translocation is a frequent cytogenetic abnormality found in hematological malignancies, occurring in 5-6% of patients with acute myeloid leukemia (AML), 7-10% of patients with acute lymphoblastic leukemia (ALL), 60-70% of infants with acute leukemia, and in most patients with therapy-related leukemia induced by inhibitors of topoisomerase II (Biondi et al., 2000; Bloomfield et al., 2002) . The MLL gene (also called ALL-1 or HRX) has been cloned in 11q23 translocations, such as t(4;11), t(9;11) and t(11;19) (Ziemin-van der Poel et al., 1991; Gu et al., 1992; Tkachuk et al., 1992) , and is translocated to approximately 60 different chromosomal loci (Hayashi, 2000; Daser and Rabbitts, 2004) . Cloning of various fusion partners of MLL has revealed that the phenotype of leukemia with MLL gene rearrangement usually depends on the fusion partner (Hayashi, 2000) . Despite the progress of cancer therapy, MLL gene rearrangement is strongly associated with a poor outcome in infants with ALL, compared with that of older children with ALL or AML (Biondi et al., 2000; Kawasaki et al., 2001; Kosaka et al., 2004) .
Recent progress in gene expression monitoring using DNA microarrays has revealed novel leukemia classification with a distinct gene expression in pediatric ALL with MLL gene rearrangement (Hayashi, 2003) . Clustering algorithms have revealed that, based on their gene expression patterns, acute leukemias with MLL rearrangement can clearly be separated from conventional ALL and AML, suggesting that they constitute a distinct disease (Armstrong et al., 2002) . We have also found that infant ALL with MLL gene rearrangement can be identified from the distinct expression pattern of several genes, including FLT3, CD44, HOXA9 and MEIS1 (Tsutsumi et al., 2003) . Intriguingly, point mutations of D835/I836 of the FLT3 gene have been frequently found in infant ALL with MLL gene rearrangement, suggesting that FLT3 mutation is a second genetic event in ALL with MLL rearrangement (Taketani et al., 2004) . Furthermore, using the gene expression profiles, each of the t(4;11), t(11;19), or t(5;11) found in ALL with MLL gene rearrangement could be classified into two distinct groups, with differential prognosis, irrespective of their translocation partner chromosomes (Tsutsumi et al., 2003) .
Several cases with complex 11q23 translocations have been identified by molecular analysis (Taki et al., 1996; Chinwalla et al., 2003) . Particularly, these translocations were frequently observed in t(10;11)(p12;q23) creating MLL-AF10 (Beverloo et al., 1995; Shibuya et al., 2001) and t(X;11)(q22-24;q23) creating MLL-SEPT6 (Ono et al., 2002a; Slater et al., 2002) , because the direction of transcription of AF10 and SEPT6 is opposite to that of MLL. Therefore in t(10;11)(p12;q23) or t(X;11)(q22-24;q23), an inversion of a part of chromosome including MLL, AF10 or SEPT6 inserts adjacent to the partner gene to form regular head-to-tail fusion transcripts (Beverloo et al., 1995; Fu et al., 2003) . In this study, we identified the MYO1F gene on chromosome 19p13 as a novel fusion partner of the MLL gene in a patient with infant acute monocytic leukemia (AMoL). To date, ENL, ELL/MEN and EEN have been identified as fusion partners of MLL in reciprocal t(11;19)(q23;p13) (Hunger et al., 1993; Thirman et al., 1994; Mitani et al., 1995; So et al., 1997) . MYO1F is the fourth partner gene of MLL on chromosome band 19p13.
Results
Rearrangement of the MLL gene in an infant AMoL patient with a complex translocation involving chromosomes 7, 11, 19 and 22 A 2-month-old girl was diagnosed as having AMoL. Cytogenetic analyses of the leukemic cells of the patient using regular G-banding and spectral karyotyping (SKY) analysis revealed 46, XX, der(7)t(7;19)(q11;p13), der(11)t(7;11)(q11;q23), del(19)(p13), der(22)t(11;22) (q23;p13) [17/20] and 46, XX [3/20] (Figure 1 ). Southern blot analysis of DNA prepared from the leukemic cells of the patient using an MLL cDNA probe showed a chromosomal breakpoint within the breakpoint cluster region of the MLL gene at 11q23 (Figure 2 ). These findings likely showed that 5 0 -MLL was fused to a gene on 7q11. Since no partner gene of MLL had been identified on chromosome 7q11, we inferred that the MLL in this patient was fused to a novel partner gene.
Cloning and identification of MLL fusion cDNA
To clone the chimeric transcripts, we performed cDNA panhandle PCR analysis of poly (A) þ RNA from the bone marrow mononuclear cells of the patient at diagnosis. We detected PCR products using primers MLL-3 and ALL-7S for the second PCR (Figure 3a) . Sequence analysis of the subcloned PCR product revealed that one clone contained only an 8-bp sequence fused to MLL exon 7 (Figure 3c ). To clone a longer sequence of the novel partner gene, we next performed second PCR for the same first PCR product using primers MLL-3 and AK76, which contains the junction of MLL exon 7 and an unknown 8-bp sequence, and 
Isolation of the MYO1F gene
A BLAST database search for the novel 42-bp sequence identified two highly homologous expressed sequence tag (EST) clones (GenBank Accession numbers BI022672 and BI911874), but no known gene sequences at that time. After several rounds of database search and reverse transcription-polymerase chain reaction (RT-PCR) followed by sequencing, we identified a more than 2-kb sequence with a continuous open reading frame. The 3 0 part of the sequence was found to match the partial sequence of the MYO1F gene (GenBank Accession numbers X98411 and U57053). More recently, two complete MYO1F sequences have been deposited to GenBank (BC028071, AJ310570). The MYO1F gene was predicted to encode a 1098-aminoacid with an N-terminal head domain containing both ATPbinding and actin-binding sequences, a neck domain with a single IQ motif, and a tail with TH1, TH2 and SH3 domains. Surprisingly, the MYO1F gene has been mapped to chromosome band 19p13.2-p13.3, the border of 19p13.2 and 19p13.3 (Hasson et al., 1996) , but not 7q11, as we expected. We also confirmed that the BAC clone including the partial MYO1F sequence (RP11-79F15) was assigned on chromosome band 19p13.2-p13.3 by fluorescence in situ hybridization analysis for normal metaphase chromosomes (data not shown).
Detection of the MLL-MYO1F fusion transcript and genomic junctions
To verify that this fusion product was indeed expressed in the leukemic cells, we performed RT-PCR analysis using primers ALL-7S and SS-2A, and obtained a fusion product of an 83-bp sequence of exon 7 in the MLL gene at the 5 0 region to a 96-bp sequence at the 3 0 region (Figure 3b) .
We next performed a database search for the MYO1F sequence and identified three overlapped genomic clones (LLNLR-269C7, LLNLR-282E1, and LLNLR-309F9). Restriction mapping by Southern blot analysis using the MYO1F probe, as well as the MLL cDNA probe (Figure 2 ), allowed us to locate both breakpoints of MLL and MYO1F (Figure 4a ). We cloned the genomic junction of the breakpoint by genomic PCR using a set of primers (ALL-7S and SS-18AG) followed by sequencing (Figure 4b) . Cloning of the genomic junction of MLL and MYO1F suggested that the chromosome translocation that occurred in the leukemic cells of this patient was not a simple 4-way translocation, but a complex translocation that could not be detected by spectral karyotyping analysis. Although the direction of transcription of MYO1F is the same as that of MLL, one possible explanation of this complex translocation is that a small portion of chromosome 19 could have been inserted into chromosome 7, which when it translocated to chromosome 11, carried 19p with it. However, we could not analyse the cytogenetic change of this complex translocation further, because samples could no longer be obtained.
Expression of the MYO1F gene in normal human tissues and leukemic cell lines
To examine expression of the MYO1F gene, we performed Northern blot analysis of poly(A) þ RNA from various human tissues using the MYO1F cDNA probe spanning exons 1-2, and detected a transcript of 
Discussion
In the present study, we isolated a novel fusion partner of the MLL gene, MYO1F, on chromosome band 19p13.2-p13.3, in de novo infant AMoL with chromosomal abnormalities involving chromosomes 7, 11, 19 and 22. MYO1F is the fourth partner gene of MLL on chromosome band 19p13. t(11;19)(q23;p13) is a recurring chromosomal translocation frequently observed in both ALL and AML. To date, three partner genes of MLL, ENL, ELL/MEN and EEN, have been identified and characterized (Hunger et al., 1993; Thirman et al., 1994; Mitani et al., 1995; So et al., 1997) . ENL has transcriptional transactivation properties (Slany et al., 1998) , and ELL/MEN is an RNA polymerase II elongation factor (Shilatifard et al., 1996) . EEN contains a central a-helical coiled-coil region and a Cterminal SH3 domain, suggesting an association with the dimerization of MLL-EEN chimeric protein (Liu et al., 2004) . These three gene products and MYO1F share no homology with each other except that EEN and MYO1F have an SH3 domain, and are predicted to be functionally different. At the cytogenetic level, it may be difficult to distinguish MLL-ENL, MLL-ELL/MEN, MLL-EEN, and MLL-MYO1F fusion, and it is likely that other cases of t(11;19) lacking known fusion genes may result in this gene fusion. That no amplified product was detected by RT-PCR in t(11;19) may be due not only to the heterogeneity of the breakpoints of the same gene, but also to the different partner genes.
MYO1F encodes the unconventional myosin type 1F (Crozet et al., 1997) , and is considered a candidate gene for nonsyndromic deafness, DFNB15 (Chen et al., 2001) . The function of MYO1F, however, is less well characterized. Myosins are molecular motors that, upon interaction with actin filaments, utilize energy from ATP hydrolysis to generate mechanical force (Oliver et al., 1999; Soldati, 2003) . The myosin superfamily of mechanoenzymes comprises 18 classes. The human genome encodes about 40 myosin genes, among which about 25 are unconventional and come from at least 11 classes. Each myosin has a conserved N-terminal motor domain (25-40% identical at the amino-acid level) that contains both ATP-binding and actin-binding sequences. Following the motor domain is a lightchain-binding 'neck' region containing 1-6 copies of a repeat element, the IQ motif, which serves as a binding site for calmodulin or other members of the EF-hand superfamily of calcium-binding proteins. At the Cterminus, each myosin class has a distinct tail domain that serves in dimerization, membrane binding, protein binding, and/or enzymatic activities, and targets each myosin to its particular subcellular location. (Hsu and Look, 2003; Daser and Rabbitts, 2004) . One mechanism leads to the aberrant activation of target genes including HOX by the fusion of MLL with transcriptional activation domains within translocation partners that are transcriptional factors and located in the nucleus, such as ENL, ELL, AF10, and AFX (Lavau et al., 1997; Luo et al., 2001; DiMartino et al., 2002; So and Cleary, 2002) . The other mechanism leads to the similar aberrant activation of target genes by the dimerization of MLL fusion proteins, through oligomerization domains within various translocation partners that are located in the cytoplasm, such as GAS7, AF1p and Gephyrin (Martin et al., 2003; So et al., 2003; Eguchi et al., 2004) . MYO1F has neither a transcriptional transactivation domain nor a dimerization domain. It remains unclear whether MLL-MYO1F leads to the development of leukemia through either mechanism, or another mechanism. In MLL-MYO1F fusion protein, C-terminal region of MLL including PHD fingers, taspase cleavage sites, transactivation domain, CBP (CREBbinding protein)-binding region, and SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) domain, which has consequences for target gene activity as the MLLmediated H3 and H4 methylation of the HOXA9 and Hoxc8 promoter, is lost, to be replaced by MYO1F (Daser and Rabbitts, 2004) . Loss of function of these domains of MLL may also be associated with leukemogenesis.
Expression of the MYO1F gene was found in all tissues examined, as previously described (Crozet et al., 1997) . The expression was particularly found in peripheral blood lymphocytes at a high level (Figure 5a ), but only in three leukemic cell lines (Figure 5b ). These findings suggest that gain-of-function by C-terminal MYO1F in fusion protein, but not lossof-function of normal MYO1F, plays some role in leukemogenesis. Further analysis is needed to clarify the role of MYO1F in normal development and leukemogenesis.
To date, a small number of myosin genes have been reported to be associated with chromosomal translocation in hematological malignancies. Smooth muscle myosin heavy chain 11, MYH11, is fused to corebinding factor beta, CBFb, in AML-M4Eo with inv(16)(p13q22) (Liu et al., 1993) , and nonmuscle myosin heavy chain (MYH9) is fused to ALK in anaplastic large cell lymphoma with t(2;22)(p23;q11.2) (Lamant et al., 2003) . Furthermore, MYO18B was identified as a candidate tumor suppressor gene at chromosome 22q12.1, and was found to be deleted, mutated and methylated in human lung cancer (Nishioka et al., 2002) . Myosin family genes might play some roles in oncogenesis. However, it remains unclear whether the gain of function of a fusion partner, the truncation of MLL or some other mechanism leads to the development of leukemia.
Materials and methods

Patient
A 2-month-old girl with anemia (Hb 7.4 g/dl), a low platelet count (21 000/ml) and a high leukocyte count (155 000/ml) containing 95% blasts in peripheral blood was diagnosed as having AMoL (FAB M5b). A bone marrow smear was hypercellular with 90% monocytic blasts, and positive for myeloperoxidase and combined esterase stain (NaF inhibitionnegative). The leukemic cells expressed CD4 (26.8%), CD13 (45.3%), CD14 (45.9%), CD33 (90.1%), CD56 (92.9%) and HLA-DR (87.6%) in the bone marrow cells. She was treated with a low dose of etoposide (VP-16) (25 mg/m 2 ), but showed no effect in the reduction of leukemic cells. She was also treated with blood exchange to reduce the blast cells. Unfortunately, she developed respiratory distress, which was controlled by mechanical ventilation. Moreover, brain echography showed intracranial hemorrhage. She died of cardiovascular failure 5 days after admission.
Leukemic cell lines
B-precursor ALL (KOCL-45, THP-4, THP-7, OM9;22 and L-SAK), B-ALL (THP-8, A4/FUK, RAMOS and DAUDI), T-ALL (L-SMY MOLT-14, THP-6 and RPMI8402), AMOL (THP-1), AML (HEL, KG-1, ML-1 and Kasumi-3) and AMKL (CMS) cell lines were analysed by Northern blot analysis (Ono et al., 2002a, b) .
Southern blot analysis
High-molecular-weight DNA was extracted from the bone marrow at diagnosis, and 10 mg of DNA was analysed, as reported previously (Ono et al., 2002b) . A 0.9-kb MLL cDNA probe (Ono et al., 2002b ) and a 243-bp MYO1F genomic probe within intron 1 (nucleotides 11 300-11 542, GenBank Accession number AC130469) were used.
RNA extraction and cDNA panhandle PCR
Poly(A)
þ RNA was extracted from the bone marrow cells at diagnosis using QuickPrep Micro mRNA Purification Kit (Amersham Biosciences, Tokyo, Japan), and analysed by a modified cDNA panhandle PCR method as previously described (Megonigal et al., 2000; Ono et al., 2002a, b) . In brief, first-strand cDNAs were synthesized with MLL-random hexamer oligonucleotide, MLL-N. After primer 1 extension with MLL-1, and extension in stem-loop templates, the sample was amplified by first PCR with ALL-6A and MLL-1. Then, one-twenty fifth of the product was used for nested PCR with MLL-3 and ALL-7S or AK76. Five microliters of the product was electrophoresed in a 3% agarose gel. The MLL-random hexamer oligonucleotides and primers used were as follows: MLL-N, 5 0 -TCGAGGAAAAGAGTGAAGAAGGGAATG TCTCNNNNNN-3 0 ; MLL-1, 5 0 -TGAAGAACGTGGTGGA CTCT-3 0 ; ALL-6A, 5 0 -GTCCAGAGCAGAGCAAACAGA -3 0 ; MLL-3, 5 0 -GTCAGAAACCTACCCCATCA-3 0 ; ALL -7S, 5 0 -TCCTCAGCACTCTCTCCAAT-3 0 ; and AK76, 5 0 -TCAGAGTGGACTTTAAGGGC-3 0 .
Nucleotide sequencing
Nucleotide sequences of the PCR products, or if necessary the subcloned PCR products, were analysed as previously described (Ono et al., 2002a, b; Hiwatari et al., 2003) .
RT-PCR and genomic PCR
Of the total RNA, 4 mg was reverse-transcribed to cDNA in a total volume of 33 ml with random hexamers using Ready-ToGo You-Prime First-Strand Beads. The conditions and reagents for PCR have been already described (Ono et al., 2002a, b; Hiwatari et al., 2003) . The primers used were as follows: ALL-7S and SS-2A, 5 0 -AATGGCGTCTTCGGT GATCTG-3 0 . In all, 40 ng of genomic DNA derived from the patient's leukemic cells was amplified under conditions identical to those for RT-PCR. The primers used were as follows: ALL-7S and SS-18AG, 5 0 -TTGTGGTGAAGGTGATGGTG-3 0 .
Northern blot analysis
Aliquots (10 mg) of total RNA derived from each cell line and multiple human tissue Northern blots (CLONTECH Laboratories, Inc., CA, USA) were analysed with a 32 P-labeled MYO1F cDNA probe (Ono et al., 2002a, b; Hiwatari et al., 2003) . A 174-bp MYO1F cDNA fragment (nucleotides 39-213 from sequences of MYO1F cDNA, GenBank Accession number BC028071) was used.
Abbreviations AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; AMoL, acute monocytic leukemia; RT-PCR, reverse transcription-polymerase chain reaction.
